down arrow

Electromed, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2854091087
USD
27.80
-0.15 (-0.54%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

27.7927.97

52 Week

17.7335.56
Valuation
Technical
Day's Volume

CASH

6.27 k

Shareholding (Mar 2025)

FII

3.45%

Held by 28 FIIs

DII

84.72%

Held by 12 DIIs

Promoter

0.00%

How big is Electromed, Inc.?

22-Jun-2025

As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million and reported net sales of 61.43 million with a net profit of 7.16 million over the last four quarters.

Market Cap: As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Electromed, Inc. reported net sales of 61.43 million and a net profit of 7.16 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company's shareholder's funds amounted to 44.55 million, while total assets were reported at 52.88 million.

Read More

What does Electromed, Inc. do?

22-Jun-2025

Electromed, Inc. develops and markets airway clearance products using High Frequency Chest Wall Oscillation therapy, with recent net sales of $16 million and a market cap of $168.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.

Overview:<BR>Electromed, Inc. develops, manufactures, and markets airway clearance products utilizing High Frequency Chest Wall Oscillation (HFCWO) therapy in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 16 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 168.31 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 25.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.35 <BR>Return on Equity: 16.30% <BR>Price to Book: 3.83 <BR><BR>Contact Details:<BR>Address: 500 6th Ave NW, NEW PRAGUE MN: 56071-1134 <BR>Tel: ['1 952 7589299', '1 212 8369614'] <BR>Website: http://smartvest.com/

Read More

Who are in the management team of Electromed, Inc.?

22-Jun-2025

As of March 2022, the management team of Electromed, Inc. includes Independent Chairman Mr. Stephen Craney, President and CEO Ms. Kathleen Skarvan, and several Independent Directors: Mr. Stan Erickson, Mr. Gregory Fluet, Ms. Lee Jones, Ms. Andrea Walsh, and Dr. George Winn. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Electromed, Inc. includes the following individuals:<BR><BR>- Mr. Stephen Craney, who serves as the Independent Chairman of the Board.<BR>- Ms. Kathleen Skarvan, who holds the positions of President, Chief Executive Officer, and Director.<BR>- Mr. Stan Erickson, who is an Independent Director.<BR>- Mr. Gregory Fluet, also serving as an Independent Director.<BR>- Ms. Lee Jones, who is an Independent Director.<BR>- Ms. Andrea Walsh, who is an Independent Director.<BR>- Dr. George Winn, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Electromed, Inc. overvalued or undervalued?

20-Sep-2025

As of August 26, 2025, Electromed, Inc. is fairly valued with a P/E ratio of 25 and an EV to EBITDA of 16.14, indicating it is priced at a premium compared to some peers, despite its previous attractive rating.

As of 26 August 2025, the valuation grade for Electromed, Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 16.14, and a PEG ratio of 0.38, which suggests that the stock may not be undervalued despite its previous attractive rating.<BR><BR>When compared to peers, Electromed's P/E ratio of 27.12 is higher than that of Clearpoint Neuro, Inc., which has a P/E of -13.98, indicating that Electromed is priced at a premium relative to some of its riskier counterparts. Additionally, the EV to EBITDA ratio for Electromed is more favorable than the average of its peers, which are generally in the risky category. Although specific return data is not available, Electromed's performance should be analyzed in the context of broader market trends, such as the S&P 500, to fully assess its valuation narrative.

Read More

Is Electromed, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Electromed, Inc. shows a neutral trend with mixed technical indicators, having outperformed the S&P 500 over the past year but underperformed year-to-date, suggesting a cautious outlook.

As of 12 September 2025, the technical trend for Electromed, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on the weekly but is mildly bearish on the monthly. Bollinger Bands are bullish on both weekly and monthly time frames, while moving averages indicate a mildly bearish trend on the daily. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows no trend on the weekly but is mildly bullish monthly. <BR><BR>In terms of performance, Electromed has outperformed the S&P 500 over the past year with a return of 22.86% compared to the S&P 500's 17.14%, and significantly outperformed over the 3-year and 5-year periods as well. However, it has underperformed year-to-date with a return of -15.43% versus the S&P 500's 12.22%. Overall, the mixed indicators suggest a cautious outlook.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 208 Million (Micro Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.35

stock-summary
Return on Equity

17.78%

stock-summary
Price to Book

4.82

Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.6%
0%
11.6%
6 Months
37.97%
0%
37.97%
1 Year
-6.71%
0%
-6.71%
2 Years
161.28%
0%
161.28%
3 Years
179.12%
0%
179.12%
4 Years
124.01%
0%
124.01%
5 Years
178.56%
0%
178.56%

Electromed, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Electromed Stock Forms Golden Cross, Signaling Potential Bullish Breakout

Electromed Stock Forms Golden Cross, Signaling Potential Bullish Breakout

Electromed, Inc. has recently achieved a Golden Cross, indicating a potential shift in market momentum. While the stock has underperformed year-to-date, it has shown significant growth over the past three and five years. Current indicators suggest a bullish trend in the short term, attracting investor attention.

Read More

Is Electromed, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Electromed, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on the weekly but is mildly bearish on the monthly. Bollinger Bands are bullish on both weekly and monthly time frames, while moving averages indicate a mildly bearish trend on the daily. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows no trend on the weekly but is mildly bullish monthly. In terms of performance, Electromed has outperformed the S&P 500 over the past year with a return of 22.86% compared to the S&P 500's 17.14%, and significantly outperformed over the 3-year and 5-year periods as well. However, it has underperformed year-to-date with a return of -15.43% versus the S&P 500's 12.22%. Overall, the mixed indicators suggest a cautious outl...

Read More

Is Electromed, Inc. overvalued or undervalued?

As of 26 August 2025, the valuation grade for Electromed, Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 16.14, and a PEG ratio of 0.38, which suggests that the stock may not be undervalued despite its previous attractive rating. When compared to peers, Electromed's P/E ratio of 27.12 is higher than that of Clearpoint Neuro, Inc., which has a P/E of -13.98, indicating that Electromed is priced at a premium relative to some of its riskier counterparts. Additionally, the EV to EBITDA ratio for Electromed is more favorable than the average of its peers, which are generally in the risky category. Although specific return data is not available, Electromed's performance should be analyzed in the context of broader market trends, such as the S&P 500, to fully assess its valuation narrative....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
14.54%
EBIT Growth (5y)
18.58%
EBIT to Interest (avg)
4.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
1.32
Tax Ratio
25.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
46.66%
ROCE (avg)
17.40%
ROE (avg)
9.49%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
4.00
EV to EBIT
17.92
EV to EBITDA
16.14
EV to Capital Employed
5.59
EV to Sales
2.61
PEG Ratio
0.38
Dividend Yield
NA
ROCE (Latest)
31.20%
ROE (Latest)
16.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 13 Schemes (11.83%)

Foreign Institutions

Held by 28 Foreign Institutions (3.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 10.83% vs -3.68% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 15.79% vs -5.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.40",
          "val2": "15.70",
          "chgp": "10.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.60",
          "val2": "2.40",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.20",
          "val2": "1.90",
          "chgp": "15.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "187.00%",
          "val2": "136.40%",
          "chgp": "5.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 13.72% vs 15.35% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 62.50% vs 39.13% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "54.70",
          "val2": "48.10",
          "chgp": "13.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.40",
          "val2": "4.60",
          "chgp": "60.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.20",
          "val2": "3.20",
          "chgp": "62.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "120.30%",
          "val2": "83.40%",
          "chgp": "3.69%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
17.40
15.70
10.83%
Operating Profit (PBDIT) excl Other Income
3.60
2.40
50.00%
Interest
0.00
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
2.20
1.90
15.79%
Operating Profit Margin (Excl OI)
187.00%
136.40%
5.06%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 10.83% vs -3.68% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 15.79% vs -5.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
54.70
48.10
13.72%
Operating Profit (PBDIT) excl Other Income
7.40
4.60
60.87%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
5.20
3.20
62.50%
Operating Profit Margin (Excl OI)
120.30%
83.40%
3.69%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is 13.72% vs 15.35% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 62.50% vs 39.13% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Electromed, Inc. stock-summary
stock-summary
Electromed, Inc.
Pharmaceuticals & Biotechnology
Electromed, Inc. develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company's products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. As of June 30, 2016, the SmartVest System is available in two models: SV2100 and SQL. The SmartVest System consists of an inflatable therapy garment, a programmable air pulse generator and a single-hose, which delivers air pulses from the generator to the garment. The SmartVest SQL System is small, quiet and light, and offers generator programmability. The Company markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to healthcare providers, particularly those working in intensive care units. The Company sells its products to the home healthcare market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis and neuromuscular disease.
Company Coordinates stock-summary
Company Details
500 6th Ave NW , NEW PRAGUE MN : 56071-1134
stock-summary
Tel: 1 952 75892991 212 8369614
stock-summary
http://smartvest.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."